Agenus (AGEN) Cost of Revenue (2010 - 2025)
Agenus (AGEN) posted quarterly Cost of Revenue of $23.5 million for Q4 2025, down 16.41% year-over-year from $28.1 million in Q4 2024, and up 3555.14% quarter-over-quarter from $642000.0 in Q3 2025.
Agenus (AGEN) Cost of Revenue (2010 - 2025) Analysis & Trends
Agenus' Cost of Revenue history runs 9 years deep, the most recent figure standing at $23.5 million for Q4 2025.
- In Q4 2025, Cost of Revenue fell 16.41% year-over-year to $23.5 million; the TTM figure through Mar 2026 stood at $24.4 million (down 14.47% YoY), while the FY2025 annual figure was $24.5 million, down 13.9% from the prior year.
- Cost of Revenue for Q4 2025 stood at $23.5 million, up from $642000.0 in the prior quarter.
- The five-year high for Cost of Revenue was $34.9 million in Q4 2023, with the low at $107000.0 in Q1 2024.
- The 5-year median for Cost of Revenue is $654500.0 (2021), against an average of $5.2 million.
- The sharpest annual moves came in 2022 and 2024: Cost of Revenue soared 773.21% in 2022, then slumped 95.34% in 2024.
- Agenus' Cost of Revenue stood at $881000.0 in 2021, then jumped by 773.21% to $7.7 million in 2022, then soared by 353.04% to $34.9 million in 2023, then dropped by 19.45% to $28.1 million in 2024, then fell by 16.41% to $23.5 million in 2025.
- Business Quant data shows AGEN's Cost of Revenue at $23.5 million in Q4 2025, $642000.0 in Q3 2025, and $243000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Agenus | 311.95 Mn | 286.43 Mn | 34.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 23.47 Mn |
| Dec 31, 2025 | 23.47 Mn |
| Sep 30, 2025 | 642,000.00 |
| Sep 30, 2025 | 642,000.00 |
| Jun 30, 2025 | 243,000.00 |
| Jun 30, 2025 | 243,000.00 |
| Mar 31, 2025 | 137,000.00 |
| Mar 31, 2025 | 137,000.00 |
| Dec 31, 2024 | 28.07 Mn |
| Dec 31, 2024 | 28.07 Mn |
| Sep 30, 2024 | 146,000.00 |
| Sep 30, 2024 | 146,000.00 |
| Jun 30, 2024 | 115,000.00 |
| Jun 30, 2024 | 115,000.00 |
| Mar 31, 2024 | 107,000.00 |
| Mar 31, 2024 | 107,000.00 |
| Dec 31, 2023 | 34.85 Mn |
| Dec 31, 2023 | 34.85 Mn |
| Sep 30, 2023 | 303,000.00 |
| Sep 30, 2023 | 303,000.00 |